C3 vs Pathway Expression

	C3	IC(Δ)	P-val	FDR
VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY_DN		0.811(0.007)	2.62e-06	2.87e-05
WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2		0.806(0.007)	2.62e-06	2.87e-05
WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_UP		0.804(0.010)	2.62e-06	2.87e-05
WAMUNYOKOLI_OVARIAN_CANCER_LMP		0.790(0.007)	2.62e-06	2.87e-05
WANG_BARRETTS_ESOPHAGUS_AND_ESOPHAGUS_CANCER_UP		0.774(0.008)	2.62e-06	2.87e-05
MIKI_COEXPRESSED_WITH_CYP19A1		0.768(0.008)	2.62e-06	2.87e-05
SERVITJA_ISLET_HNF1A_TARGETS_DN		0.766(0.008)	2.62e-06	2.87e-05
WAMUNYOKOLI_OVARIAN_CANCER_LMP_UP		0.764(0.008)	2.62e-06	2.87e-05
ZHOU_PANCREATIC_EXOCRINE_PROGENITOR		0.759(0.007)	2.62e-06	2.87e-05
ZEMBUTSU_SENSITIVITY_TO_VINBLASTINE		0.757(0.007)	2.62e-06	2.87e-05
GRADE_COLON_AND_RECTAL_CANCER		0.745(0.008)	2.62e-06	2.87e-05
KEGG_MATURITY_ONSET_DIABETES_OF_THE_YOUNG		0.745(0.009)	2.62e-06	2.87e-05
VANDESLUIS_COMMD1_TARGETS_GROUP_3		0.738(0.007)	2.62e-06	2.87e-05
DOANE_RESPONSE_TO_ANDROGEN		0.738(0.008)	2.62e-06	2.87e-05
LIU_CDX2_TARGETS_UP		0.738(0.008)	2.62e-06	2.87e-05
WATANABE_RECTAL_CANCER_RADIOTHERAPY_RESPONSIVE_UP		0.736(0.009)	2.62e-06	2.87e-05
PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQUE		0.735(0.007)	2.62e-06	2.87e-05
RNA_CATABOLIC_PROCESS		0.734(0.009)	2.62e-06	2.87e-05
RODRIGUES_NTN1_TARGETS_DN		0.733(0.008)	2.62e-06	2.87e-05
KEGG_HISTIDINE_METABOLISM		0.730(0.009)	2.62e-06	2.87e-05
REACTOME_AXON_GUIDANCE		-0.708(0.008)	2.62e-06	1.63e-05
WOO_LIVER_CANCER_RECURRENCE		-0.710(0.009)	2.62e-06	1.63e-05
BOQUEST_STEM_CELL		-0.712(0.007)	2.62e-06	1.63e-05
GROGER_EMT		-0.712(0.009)	2.62e-06	1.63e-05
LE_SKI_TARGETS_DN		-0.713(0.010)	2.62e-06	1.63e-05
CAIRO_LIVER_DEVELOPMENT_UP		-0.716(0.008)	2.62e-06	1.63e-05
LIM_MAMMARY_STEM_CELL		-0.718(0.008)	2.62e-06	1.63e-05
WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_DN		-0.718(0.010)	2.62e-06	1.63e-05
PID_S1P_S1P4_PATHWAY		-0.720(0.011)	2.62e-06	1.63e-05
MCCLUNG_DELTA_FOSB_TARGETS_8WK		-0.728(0.009)	2.62e-06	1.63e-05
CHEN_HOXA5_TARGETS_6HR_DN		-0.729(0.009)	2.62e-06	1.63e-05
GRADE_COLON_AND_RECTAL_CANCER_DN		-0.734(0.008)	2.62e-06	1.63e-05
LEF1_UP.V1		-0.735(0.010)	2.62e-06	1.63e-05
VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY_UP		-0.736(0.008)	2.62e-06	1.63e-05
CAIRO_LIVER_DEVELOPMENT		-0.743(0.007)	2.62e-06	1.63e-05
LABBE_TARGETS_OF_TGFB1_AND_WNT3A		-0.748(0.008)	2.62e-06	1.63e-05
SERVITJA_ISLET_HNF1A_TARGETS		-0.756(0.008)	2.62e-06	1.63e-05
WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN		-0.764(0.008)	2.62e-06	1.63e-05
REACTOME_SIGNALING_BY_ROBO_RECEPTOR		-0.775(0.008)	2.62e-06	1.63e-05
VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY		-0.825(0.006)	2.62e-06	1.63e-05